During clinical use, Acapsil has been found to effectively promote the healing of a wide range of acute and chronic wounds and ulcers and without giving rise to adverse events. The following is a brief summary and more detail can be found on accompanying pages.
Comparative clinical study of Acapsil, Antibiotic and Antiseptic
The purpose was to evaluate the wound healing effects of Acapsil and to compare it to antibiotics and antiseptics. The study included 266 patients with a wide range of wounds and ulcers, which were severely colonised to infected. Acapsil reduced the time to achieving a clean wound, i.e. free of necrosis, pus and fibrinogenous thickenings, by 60% compared to the topical antibiotic and the antiseptic. Furthermore, Acapsil reduced the number of hospitalisation-days by 31% and accelerated the rate of wound closure. See more.
Clinical evaluation on 9 dehisced surgical wounds and 1 category 4 pressure ulcer
Acapsil was evaluated in a clinical audit at Bristol University Hospital on 9 dehisced surgical wounds and a category 4 pressure ulcer. Several of the wounds displayed more than 40% slough and signs of local infection. Acapsil rapidly lifted the slough off and facilitated a rapid build-up of granulation tissue such that the wounds continued towards full closure much faster than normal. An average of 3 applications was used on the wounds to reach a clean actively healing wound. According to the responsible TVN, these wounds would normally have required 1 week with UrgoClean to remove the slough followed by 2 or more weeks with TNP to reach the same stage as that achieved with 3 applications of Acapsil. None of the wounds became chronic. See more.
Clinical evaluation of MPPT in pyoderma gangrenosum
University Hospital Birmingham, UK, evaluated MPPT in three patients with chronic inactive stable PG ulcers. See more.
Selected case reports to demonstrate the use of Acapsil on specific wound types. Acapsil has been able to initiate the healing of several non-healing wounds and ulcers, which had not responded to a wide range of approaches. See more.
Prior to conducting the clinical studies, Acapsil was evaluated in a preclinal model of wound healing. Acapsil was compared to Gentaxane and untreated controls. It was found that Acapsil (MPPT) removed the wound infection and initiated healing 60% quicker then both Gentaxane and Control. This is the exact same level of reduction as seen in the clinical study. Acapsil is avaliable for use in veterinary wound care under the name SertaSil. See the study here.
The potential healthcost savings that could be achieved by the implementation of Acapsil were determined using 1) a population approach based on available data on wounds and their associated costs and 2) individual case reports. The overall level of potential savings was estimated at 21%. See more.